A.R.T. Advisors’s Intellia Therapeutics NTLA Stock Holding History

A.R.T. Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-67,097	Closed	-$896K	–	1599
2019 Q3	$896K	Sell	67,097 -37,500	-36%	-$598K	0.04%	599
2019 Q2	$1.71M	Buy	104,597 +45,900	+78%	+$722K	0.1%	276
2019 Q1	$1M	Buy	+58,697	New	+$875K	0.06%	482
2017 Q2	–	Sell	-10,541	Closed	-$148K	–	1627
2017 Q1	$148K	Buy	+10,541	New	+$141K	0.01%	1219

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

A.R.T. Advisors's NTLA Position: Q4 2019 in Review

A.R.T. Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2019, closing a stake of 67,097 shares — an estimated $896K sold.

A.R.T. Advisors first reported a position in NTLA in Q1 2017 and held it in 4 quarters. The position peaked at $1.71M in Q2 2019. 143 funds tracked by Wall St. Rank hold NTLA as of Q4 2019.

A.R.T. Advisors reported no remaining Intellia Therapeutics position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 67,097 Intellia Therapeutics shares in Q4 2019, an estimated $896K.
A.R.T. Advisors first reported a position in Intellia Therapeutics in Q1 2017 and held it in 4 quarters.
A.R.T. Advisors's Intellia Therapeutics position peaked at $1.71M in Q2 2019.
143 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.